| Karen Kelly, MD | |
|
600 Moye Blvd, Greenville, NC 27834-4300 | |
| (252) 744-2803 | |
| (252) 744-3616 |
| Full Name | Karen Kelly |
|---|---|
| Gender | Female |
| Speciality | Pathology - Anatomic Pathology & Clinical Pathology |
| Location | 600 Moye Blvd, Greenville, North Carolina |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134365653 | NPI | - | NPPES |
| 151HV | Other | NC | BCBS NC |
| 5911595 | Medicaid | NC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 2008-01993 (North Carolina) | Primary |
| Entity Name | East Carolina University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972551919 PECOS PAC ID: 0244143246 Enrollment ID: O20031106000400 |
News Archive
Extremely premature baby girls, especially those who are African American, are much more likely to survive than extremely premature white boys, according to research published in the January issue of Pediatrics.
Broward Health Medical Center, home to the Broward Health Graduate Medical Education Simulation Lab in Fort Lauderdale, Fla., has become the first United States medical institution to receive the VirtaMed LaparoS™ surgical training simulator. This mixed reality laparoscopic simulator provides resident doctors with a simulated environment to prepare for clinical practice safely and efficiently.
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the presentation of preclinical research describing the mechanism of action of otelixizumab at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD). In addition, Tolerx also announced that the first European patient was enrolled in DEFEND-2, a confirmatory Phase 3 clinical trial evaluating otelixizumab in autoimmune new-onset type 1 diabetes.
Nephron sparing surgery for localized renal tumors has gained increasing acceptance as a standard of care in appropriately selected patients.
Veloxis Pharmaceuticals and Athena Drug Delivery Solutions Pvt. Ltd. today announced an alliance whereby Athena will obtain exclusive rights in certain emerging market territories to manufacture and, with third parties, develop, register and commercialize Veloxis' AtorFen (Fenofibrate Atorvastatin fixed dose combination).
› Verified 1 days ago
| Entity Name | Ecu Physicians Diagnostic Pathology Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558695288 PECOS PAC ID: 8325181167 Enrollment ID: O20100202000776 |
News Archive
Extremely premature baby girls, especially those who are African American, are much more likely to survive than extremely premature white boys, according to research published in the January issue of Pediatrics.
Broward Health Medical Center, home to the Broward Health Graduate Medical Education Simulation Lab in Fort Lauderdale, Fla., has become the first United States medical institution to receive the VirtaMed LaparoS™ surgical training simulator. This mixed reality laparoscopic simulator provides resident doctors with a simulated environment to prepare for clinical practice safely and efficiently.
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the presentation of preclinical research describing the mechanism of action of otelixizumab at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD). In addition, Tolerx also announced that the first European patient was enrolled in DEFEND-2, a confirmatory Phase 3 clinical trial evaluating otelixizumab in autoimmune new-onset type 1 diabetes.
Nephron sparing surgery for localized renal tumors has gained increasing acceptance as a standard of care in appropriately selected patients.
Veloxis Pharmaceuticals and Athena Drug Delivery Solutions Pvt. Ltd. today announced an alliance whereby Athena will obtain exclusive rights in certain emerging market territories to manufacture and, with third parties, develop, register and commercialize Veloxis' AtorFen (Fenofibrate Atorvastatin fixed dose combination).
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Karen Kelly, MD Po Box 751069, Charlotte, NC 28275-1069 Ph: () - | Karen Kelly, MD 600 Moye Blvd, Greenville, NC 27834-4300 Ph: (252) 744-2803 |
News Archive
Extremely premature baby girls, especially those who are African American, are much more likely to survive than extremely premature white boys, according to research published in the January issue of Pediatrics.
Broward Health Medical Center, home to the Broward Health Graduate Medical Education Simulation Lab in Fort Lauderdale, Fla., has become the first United States medical institution to receive the VirtaMed LaparoS™ surgical training simulator. This mixed reality laparoscopic simulator provides resident doctors with a simulated environment to prepare for clinical practice safely and efficiently.
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the presentation of preclinical research describing the mechanism of action of otelixizumab at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD). In addition, Tolerx also announced that the first European patient was enrolled in DEFEND-2, a confirmatory Phase 3 clinical trial evaluating otelixizumab in autoimmune new-onset type 1 diabetes.
Nephron sparing surgery for localized renal tumors has gained increasing acceptance as a standard of care in appropriately selected patients.
Veloxis Pharmaceuticals and Athena Drug Delivery Solutions Pvt. Ltd. today announced an alliance whereby Athena will obtain exclusive rights in certain emerging market territories to manufacture and, with third parties, develop, register and commercialize Veloxis' AtorFen (Fenofibrate Atorvastatin fixed dose combination).
› Verified 1 days ago
Dr. John D Christie, MD, PHD Pathology Medicare: Not Enrolled in Medicare Practice Location: 600 Moye Blvd, Ecu Physicians Pathology Brody Outpatient Center, Greenville, NC 27834 Phone: 252-744-2803 Fax: 252-744-3616 | |
Cisley Cassmirra Hines, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 600 Moye Blvd, Greenville, NC 27834 Phone: 252-744-2183 Fax: 252-744-3616 | |
Dr. Joseph P Pestaner, MD Pathology Medicare: Medicare Enrolled Practice Location: 600 Moye Blvd, Ecu Physicians Pathology, Greenville, NC 27834 Phone: 252-744-2803 Fax: 252-744-3616 | |
Shoujun Chen, MD, PHD Pathology Medicare: Accepting Medicare Assignments Practice Location: 600 Moye Blvd, Greenville, NC 27834 Phone: 252-744-2803 Fax: 252-744-3616 | |
Dr. Kim Robert Geisinger, MD Pathology Medicare: Medicare Enrolled Practice Location: 600 Moye Blvd, Greenville, NC 27834 Phone: 252-744-2803 Fax: 252-744-3616 | |
Dr. Lydia Franks, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 600 Moye Blvd, Brody Outpatient Center, Greenville, NC 27834 Phone: 252-744-5911 |